Evidence map›Paper›PMID 35261539›Full record

ReviewBulletin of the National Research Centre2022

Current challenges in different approaches to control COVID-19: a comprehensive review.

Simran Giri, Sanjukta Sen, Rohan Singh, Paramita Paul, Ranabir Sahu, Gouranga Nandi, Tarun Kumar Dua

Open access · diamondAbstract readReview
In one paragraph

Review in Bulletin of the National Research Centre, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Simran GiriDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Sanjukta SenDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Rohan SinghDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Paramita PaulDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Ranabir SahuDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Gouranga NandiDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.
Tarun Kumar DuaDepartment of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur, P.O.- NBU, District- Darjeeling, West Bengal 734013 India.ORCID 0000-0001-5136-7564
North Bengal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The World Health Organization declared the outbreak of the novel coronavirus (COVID-19) as a global health emergency on January 30, 2020, and as a pandemic disease on March 11, 2020. This review highlights the international situation, risk factors, and related protections to be taken as prerequisite measures and probable treatment options for the COVID-19-infected population in the current scenario. Main text: The SARS-CoV-2 viruses and their variants caused mild-to-severe respiratory tract infection and used airborne pathways as a way of contagion. Human-to-human transmission led to an exponential growth in the rise in the number of cases making it a real burden to immobilize the rapid spread of the virus while asymptomatic patients created ambiguity for confirmation in the community. It was clear from the case studies of patients that most of them were asymptomatic but still vulnerable to the people around, and hence, in a flash, many countries around the globe went into a complete lockdown, influencing the economy and thrashing industrial outputs. On the other hand, numerous researches were made to counteract the spread through studies in antiviral therapy, immune-based therapy, vaccination development, and natural remedies. Conclusion: Although exploration for a specific drug required for the COVID-19 treatment is under extensive research worldwide and some of them are in clinical trial now. Virtual drug library screening is one of the current techniques for repurposing accessible compounds. This review could provide beneficial information about the potential current and future treatment strategies to treat the pandemic COVID-19 infection.

Indexed as

AirborneCoronavirusCOVID-19PandemicRespiratorySARS-CoV-2Treatment of COVID-19

Identifiers

PMID35261539
PMCPMC8892405
OpenAlexW4214883356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.